From: Nanobody: a promising toolkit for molecular imaging and disease therapy
Target | Nanobody (with the format of nanobody) | Tracer | Maximum uptake of the lesion (with time for imaging post-injection) | References |
---|---|---|---|---|
HER1 | 8B6 (monovalent) | 99mTc | 5.2 ± 0.5 %IA/cm3 (3 h) | [26] |
7C12 (monovalent) | 99mTc | 4.55 ± 0.24 %IA/cm3 (1 h) | ||
7D12 (monovalent, bivalent) | 99mTc | 4.62 ± 0.36 %IA/cm3 (1 h and 3 h) | ||
OA-cb6 (monovalent) | 99mTc | 2.93 ± 0.46 %ID/g (4 h) | ||
HER2 | 2Rs15d (monovalent) | 99mTc, 68Ga, 18F | 4.23 ± 0.99 %IA/g (1 h) | |
11A4 (with IRDye 800CW) | IRDye 800CW | 1.8 ± 0.5 %ID/g (1 h) | [33] | |
5F7GGC (monovalent) | 131I, 18F | 24.50 ± 9.89 %ID/g (8 h, 1 h) | [84] | |
HER3 | MSB0010853 (monovalent) | 89Zr | 6.2 ± 1.1 %ID/g (24 h) | [34] |
HGF | 1E2 and 6E10 (fused to albumin) | 89Zr | 8.9% ± 1.0 %ID/g (unknown) | [35] |
CEA | NbCEA5 (with humanized nanobody scaffold) | 99mTc | 7.09 ± 1.36 %IA/cm3 (1 h) | [36] |
MMR | α-MMR Nb (monovalent) | 99mTc | 3.02 ± 0.10 %IA/g (3 h) | [52] |
MMR 3.49 (monovalent) | 99mTc, 68Ga, 18F | 2.40 ± 0.46 %IA/g (1 h) | ||
VCAM1 | cAbVCAM1-5 (monovalent) | 99mTc, 64Cu, 18F | 2.99 ± 0.07 %ID/g (2 h) | |
VSIG4 | NbV4m119 (monovalent) | 99mTc | 0.01–0.08 %IA/g (1 h and 3 h) | |
PD-L1 | Nb109 (monovalent) | 68Ga | 4.94 ± 0.46 %ID/g (1 h) | [69] |
CAIX | B9 (with IRDye 800CW) | IRDye 800CW | 4.6 ± 0.8 %ID/g (2 h) |